Cargando…
Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy
The introduction of novel frontline agents in multiple myeloma (MM), like immunomodulatory drugs and proteasome inhibitors, has improved the overall survival of patients. Yet, MM is still not curable, and drug resistance (DR) remains the main challenge. To improve the understanding of DR in MM, we e...
Autores principales: | Bosseler, Manon, Marani, Vanessa, Broukou, Angelina, Lequeux, Amandine, Kaoma, Tony, Schlesser, Vincent, François, Jean-Hugues, Palissot, Valérie, Berchem, Guy J., Aouali, Nasséra, Janji, Bassam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032243/ https://www.ncbi.nlm.nih.gov/pubmed/29882856 http://dx.doi.org/10.3390/ijms19061551 |
Ejemplares similares
-
Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells
por: Aouali, Nassera, et al.
Publicado: (2015) -
Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy
por: Lequeux, Audrey, et al.
Publicado: (2021) -
The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model
por: Sauvage, Delphine, et al.
Publicado: (2022) -
The actin filament cross-linker L-plastin confers resistance to TNF-α in MCF-7 breast cancer cells in a phosphorylation-dependent manner
por: Janji, Bassam, et al.
Publicado: (2010) -
The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation
por: Noman, Muhammad Zaeem, et al.
Publicado: (2022)